Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACP-103 in Parkinson's Disease Psychosis
NCT00087542Phase 2Completed
- Sponsor
- Acadia Pharmaceuticals
- Start
- Mar 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing ACP-103 with Placebo (2 arms). Primary endpoint: Motoric Tolerability (UPDRS) at 4 weeks. Started Mar 2004; status: completed.
02
Drugs
pimavanserin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00087542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087542.